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and the 2013 Guidelines*
Harvey S. Hecht, MDT he Bible offers mixed messages on whetherthe sins of the fathers (and mothers) are tobe passed on to the children. In the world
of cardiovascular disease, however, the answer is un-
equivocally and unfortunately in the afﬁrmative,
as highlighted in the paper by Paixao et al. (1) in
this issue of iJACC, documenting the critical impor-
tance of a family history (FH) of coronary artery dis-
ease. In the Dallas Heart Study, 2,390 primary
prevention patients, mean age 44 years, underwent
coronary artery calcium (CAC) scanning and were
followed for a mean of 8.1  1.2 years. There were
76 coronary heart disease (CHD) events: 17 deaths,SEE PAGE 67938 nonfatal myocardial infarctions, 16 percutaneous
coronary interventions, and 5 coronary artery
bypass graft surgeries. After adjustment for tradi-
tional risk factors, a FH of coronary artery disease
in any ﬁrst-degree relative was associated with a
hazard ratio (HR) of 2.6 (p < 0.001), which was
unchanged after adjusting for CAC. The event rates
were 8.8% in those with both FH and CAC, 3.3% in
those with prevalent CAC alone, 1.9% with FH alone,
and 0.4% in those with neither FH nor CAC. The
addition of FH to CAC increased the c-statistic from
0.86 to 0.87 (p ¼ 0.037). The results were unchanged
when a premature FH (age <50 years in males and
<55 years in females) was substituted for any FH. The
greater prominence of the results in younger (age
#45 years inmales and#55 years in females) compared
with older patients (HRs: 5.1 vs. 2.0, p ¼ 0.007) is of
particular importance because the younger cohort is
virtually ignored by risk factor–based paradigms.* Editorials published in JACC: Cardiovascular Imaging reﬂect the
views of the authors and do not necessarily represent the views of
JACC: Cardiovascular Imaging or the American College of Cardiology.
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Medical Systems.The FH arena is complicated by varying deﬁnitions.
Classically, premature FH is deﬁned as the onset of
clinical disease in male ﬁrst-degree relatives age <55
years and females <65 years. Alternatively, prema-
ture FH in the PROCAM (Prospective Cardiovascular
Münster trial) score and Reynolds risk score is deﬁned
as onset in either males or females at age <60 years.
Only rarely is the onset at any age utilized. However,
data from the Physicians’ Health Study and Women’s
Health Study suggest that FH at any age, particularly
maternal history, is important. Whatever the deﬁni-
tion, FH has been universally accepted as a risk
factor, but has not been universally incorporated into
risk equations; the Framingham risk score and the
EuroSCORE do not include FH. The mechanism
for the increased risk, other than the transmission of
lipid and blood pressure abnormalities, is unclear.
Inherited abnormalities of coagulation, inﬂammation,
and endothelial function have been postulated.
SINS OF THE GUIDELINES
The 2013 American College of Cardiology (ACC)/
American Heart Association (AHA) Guideline on the
Treatment of Blood Cholesterol to Reduce Athero-
sclerotic Cardiovascular Risk in Adults (2) and the 2013
ACC/AHA Guideline on the Assessment of Cardiovas-
cular Risk (3) have been quite controversial; this dis-
cussion will be limited to the role, or lack thereof, of
FH and CAC. On the basis of the assumption that
the goal of guidelines is to utilize the most powerful
predictors of risk to direct treatment, it is incom-
prehensible that the 2 most powerful risk predictors,
that is, CAC and FH, have been trivialized and down-
graded from earlier documents, rather than further
upgraded on the basis of robust data published
after the 2010 ACCF/AHA Guideline for Assessment
of Cardiovascular Risk in Asymptomatic Adults (4).
FAMILY HISTORY. The 2010 report awarded FH a Class
I recommendation, Level of Evidence: B (4). Since
then, there have been multiple reports in populations
ranging from 12,000 to almost 4 million patients (5),
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688further strengthening the case for FH as a critical risk
factor. The response of the 2013 guideline was to
downgrade FH to a Class IIb recommendation: “If,
after quantitative risk assessment, a risk based treat-
ment decision is uncertain, assessment of.family
history.may be considered” (2). The justiﬁcation was
the failure of FH to add signiﬁcantly to the c-statistic
of the new risk equation by their undocumented
analysis, despite the abundant literature to the con-
trary (5). For example, in the intermediate-risk group
in MESA (Multi-Ethnic Study of Atherosclerosis), FH
increased the area under the Framingham Risk Score
receiver-operating characteristic curve (from 0.623 to
0.675, p ¼ 0.001), second only to CAC (from 0.623 to
0.784, p < 0.001), with a net reclassiﬁcation index
(NRI) of 16%, again second only to CAC (65.9%) (6). FH
was superior to the ankle-brachial index, carotid
intima-media thickness, and high-sensitivity C-reac-
tive protein. Although the authors of the 2013 guide-
line (2) are to be congratulated for including FH, the
downgrading to Class IIb and its application only to
those few who are not in their 4 risk categories renders
the inclusion of FH almost meaningless.
CORONARY ARTERY CALCIUM. A review of the
rationale for downgrading CAC is instructive: “the
outcomes in the studies reviewed by Peters et al. and
by Greenland et al. were CHD outcomes, not hard
ASCVD [atherosclerotic cardiovascular disease]
events that included stroke; hence, uncertainty re-
mains regarding the contribution of assessing CAC to
estimating 10-year risk of ﬁrst hard ASCVD events”
(2). In other words, the outcomes were changed to
include stroke, and because there was a paucity of
stroke-related CAC data, the extraordinary body of
coronary-related CAC data was trivialized.
The rationale continues: concerns regarding costs
and radiation exposure “resulted in a decision in
the current guideline to make assessment of CAC a
Class IIb recommendation among individuals for
whom a risk-based treatment decision is uncertain
after formal risk estimation” (2). In fact, the cost of
CAC scanning has dramatically decreased to the
w$100 level, and a recent analysis demonstrated that
treating 7.5% of 10-year-risk patients with statins at a
$1/pill cost who had CAC >0 resulted in a cost per
quality-adjusted life year saved of $18,000 compared
with $78,000 for risk factor assessment alone (7). The
radiation issue has become less relevant because the
dosage has progressively decreased to #1 mSv.
Reading further: “The Work Group notes that this
Class IIb recommendation is consistent with the re-
commendations in the 2010 ACCF/AHA guideline for
patients with a 10-year CHD risk of <10%” (2). How-
ever, it is totally inconsistent with the Class IIa 2010guideline recommendation for the 10% to 20% group
(4), which is now excluded from CAC evaluation
because they will all receive statins by the new re-
commendations. It is precisely this very large group for
which the NRI by CAC in 3 major population-based
prospective outcome studies (MESA, Heinz Nixdorf
Recall, and Rotterdam) has ranged from 52% to 66%!
Moreover, as demonstrated in the Dallas Heart Study
(1) and in every study comparing CAC with conven-
tional risk factor–based assessment, CAC is superior to
risk factors. The most persistent criticism of CAC has
been the absence of randomized controlled trials
(RCTs) that demonstrate its ability to improve out-
comes. However, to continue from the 2013 guide-
line, “The Work Group acknowledges that none of
the risk assessment tools.examined in the present
document have been formally evaluated in random-
ized controlled trials” (2).
In summary, the 2013 guideline, under the rubric of
dedication to RCTs, has presented a non-RCT–
validated risk assessment paradigm that is erroneous
in at least 50% of the 7.5% to 20.0% 10-year-risk
group based on the CAC NRI in multiple prospective
studies, and have downgraded CAC and FH to a Class
IIb recommendation for whom only those few pa-
tients who are not in their 4 primary risk categories
will be eligible. Moreover, the downgrading of CAC
was rationalized by a restructuring of the outcome
deﬁnition to include stroke, which conveniently
excluded CAC from playing a major role, as well as by
erroneous cost and radiation concerns.
ATONEMENT
As the authors state: “Periodic updating of the
guidelines should address numerous issues related to
risk assessment” (2). This periodic updating should
take place immediately, with restoration of FH
and CAC at least to the 2010 risk guideline levels of
Classes I and IIa, respectively, with applicability of FH
to everybody and CAC to the 7.5% to 20.0% 10-year-
risk population. In the meantime, doctors and pa-
tients should take solace in, and advantage of, the
most enlightened 2013 guideline statement: “These
guidelines are not a replacement for clinical judg-
ment; they are meant to guide and inform decision
making.” Doctors and patients should exercise their
judgment, ignore the current CAC and FH recom-
mendations, and follow the 2010 risk guideline (4).
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